Cargando…

Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials

BACKGROUND: Acute respiratory distress syndrome (ARDS) is a potentially fatal disease with high mortality. Our aim was to summarize the current evidence for use of neuromuscular blocking agents (NMBA) in the early phase of ARDS. METHODS: Systematic review and meta-analysis of publications between 19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neto, Ary Serpa, Pereira, Victor Galvão Moura, Espósito, Daniel Crepaldi, Damasceno, Maria Cecília Toledo, Schultz, Marcus J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475105/ https://www.ncbi.nlm.nih.gov/pubmed/22835162 http://dx.doi.org/10.1186/2110-5820-2-33

Ejemplares similares

Lower tidal volumes in Brazil, also in patients without acute respiratory distress syndrome?
por: Neto, Ary Serpa, et al.
Publicado: (2013)

Neuromuscular blocking agents for acute respiratory distress syndrome
por: Torbic, Heather, et al.
Publicado: (2019)

Neuromuscular blocking agents in patients with acute respiratory distress syndrome: a summary of the current evidence from three randomized controlled trials
por: Pereira, VGM
Publicado: (2013)

Recent advances in mechanical ventilation in patients without acute respiratory distress syndrome
por: Serpa Neto, Ary, et al.
Publicado: (2014)

Is it appropriate for acute respiratory distress syndrome patients with neuromuscular blocking agents?
por: Tan, Zhimin, et al.
Publicado: (2023)

Obesity and survival in critically ill patients with acute respiratory distress syndrome: a paradox within the paradox
por: Ball, Lorenzo, et al.
Publicado: (2017)

Neuromuscular blocking agents for acute respiratory distress syndrome: how did we get conflicting results?
por: Torbic, Heather, et al.
Publicado: (2019)

Neuromuscular blocking agents for acute respiratory distress syndrome: an updated meta-analysis of randomized controlled trials
por: Zheng, Zhongjun, et al.
Publicado: (2020)

Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials
por: Tarazan, Nehal, et al.
Publicado: (2020)

Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study
por: Courcelle, Romain, et al.
Publicado: (2020)

Role of Neuromuscular Blocking Agents in Acute Respiratory Distress Syndrome: An Updated Meta-Analysis of Randomized Controlled Trials
por: Wei, Xue-biao, et al.
Publicado: (2020)

Validation of neuromuscular blocking agent use in acute respiratory distress syndrome: a meta-analysis of randomized trials
por: Chang, Wei, et al.
Publicado: (2020)

Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials
por: Alhazzani, Waleed, et al.
Publicado: (2013)

The Implementation of Protocol-Based Utilization of Neuromuscular Blocking Agent Using Clinical Variables in Acute Respiratory Distress Syndrome Patients
por: Hadique, Sarah, et al.
Publicado: (2021)

Optimizing perioperative mechanical ventilation as a key quality improvement target
por: Schultz, Marcus J., et al.
Publicado: (2015)

Association of intensity of ventilation with 28-day mortality in COVID-19 patients with acute respiratory failure: insights from the PRoVENT-COVID study
por: Schuijt, Michiel T. U., et al.
Publicado: (2021)

Early neuromuscular blocking agents for adults with acute respiratory distress syndrome: a systematic review, meta-analysis and meta-regression
por: Shao, Shuai, et al.
Publicado: (2020)

Should we treat fever in critically ill patients? A summary of the current evidence from three randomized controlled trials
por: Serpa, Ary, et al.
Publicado: (2014)

Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts
por: Bos, Lieuwe D J, et al.
Publicado: (2021)

Prolonged neuromuscular blockade by non-depolarizing neuromuscular blocking agents
por: Higashi, Michiko, et al.
Publicado: (2019)

Pragmatic Recommendations for the Management of Acute Respiratory Failure and Mechanical Ventilation in Patients with COVID-19 in Low- and Middle-Income Countries
por: Serpa Neto, Ary, et al.
Publicado: (2021)

Higher PEEP for acute respiratory distress syndrome: a Bayesian meta-analysis of randomised clinical trials
por: Neto, Ary Serpa, et al.
Publicado: (2023)

Ventilatory support of patients with sepsis or septic shock in resource-limited settings
por: Serpa Neto, Ary, et al.
Publicado: (2015)

Battling COVID-19-related mortality: from a fight for ventilators to a cry for oxygen
por: Schultz, Marcus J, et al.
Publicado: (2021)

Flexible organic frameworks sequester neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo
por: Wu, Yan, et al.
Publicado: (2022)

Neuromuscular blocking agents in the intensive care unit
por: Rodríguez-Blanco, Jonathan, et al.
Publicado: (2022)

Automation to improve lung protection
por: Buiteman-Kruizinga, Laura A., et al.
Publicado: (2022)

Tracheal Intubation Without the Use of Neuromuscular Blocking Agents
por: Prakash, Smita
Publicado: (2012)

Effect of a low versus intermediate tidal volume strategy on pulmonary complications in patients at risk of acute respiratory distress syndrome—a randomized clinical trial
por: de Haro, Candelaria, et al.
Publicado: (2023)

Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome: a pooled analysis of four observational studies
por: Pisani, Luigi, et al.
Publicado: (2021)

Urgent intubation without neuromuscular blocking agents and the risk of tracheostomy
por: Fujinaga, Jun, et al.
Publicado: (2019)

The use of a neuromuscular blocking agent could significantly decrease mortality in moderate-to-severe ARDS patients: is moderate ARDS the best indication for neuromuscular blocking agents
por: Honore, Patrick M., et al.
Publicado: (2020)

Neuromuscular blockers in the acute respiratory distress syndrome: A meta-analysis
por: Hua, Yusi, et al.
Publicado: (2020)

Novel Insights on MRGPRX2-Mediated Hypersensitivity to Neuromuscular Blocking Agents And Fluoroquinolones
por: Elst, Jessy, et al.
Publicado: (2021)

Patients with uninjured lungs may also benefit from lung-protective ventilator settings
por: Alencar, Roger, et al.
Publicado: (2017)

Clinical characteristics, physiological features, and outcomes associated with hypercapnia in patients with acute hypoxemic respiratory failure due to COVID–19---insights from the PRoVENT–COVID study
por: Tsonas, Anissa M., et al.
Publicado: (2022)

Sugammadex as a reversal agent for neuromuscular block: an evidence-based review
por: Schaller, Stefan Josef, et al.
Publicado: (2013)

Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents
por: Kim, Yong Byum, et al.
Publicado: (2017)

Potential cross-allergic reaction from pholcodine and neuromuscular blocking agents
Publicado: (2022)

Choice of neuromuscular block reversal agent to reduce postoperative pulmonary complications
por: Cho, Sung-Ae, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d75l4ige4jph7np0oud7g1d6ie